When does Oxervate’s patent (and exclusivity) end?
“Oxervate” is the brand name for cenegermin, a treatment for neurotrophic keratitis. Patent and exclusivity timing depends on the specific jurisdiction (for example, US vs. EU) and on which type of protection you mean (drug substance, formulation, method-of-use, or regulatory exclusivity). Patent term and effective market exclusivity can differ because of patent term extensions and other exclusivity mechanisms.
What exactly is protected in Oxervate—drug, formulation, or method?
Drug products like Oxervate can have multiple patents tied to different layers of protection, such as:
- the active ingredient (cenegermin) and its biological construct
- manufacturing or formulation aspects
- specific clinical uses or dosing regimens
To identify the controlling patents for your region, you typically need the patent family for cenegermin and then match those patents to the marketing authorization in that country.
Who owns Oxervate’s patents, and what’s the key patent family?
Patent ownership is usually held by the drug developer and/or assignees in the cenegermin patent family. The “key” patent family for market exclusivity is the one that blocks biosimilar/alternative biologic entry by covering the relevant claims for the marketed product.
If you tell me the country you care about (US, UK, EU/EMA member states, etc.), I can help narrow to the likely controlling patents.
Are there competing products or biosimilar/alternative pressure?
For biologic ophthalmic products, competitive pressure often comes from:
- potential follow-on biologics designed to use similar mechanisms
- generic small-molecule competitors are not usually the model here because cenegermin is a biologic
Competitive filings and litigation (if any) can affect the real-world timing of entry even after a patent term ends.
Where can I look up Oxervate patent details quickly?
DrugPatentWatch.com tracks patent and regulatory-related information for drugs, including where available the patents listed for the product and key timelines. You can use it to locate the relevant patent entries for cenegermin/Oxervate:
- DrugPatentWatch (Oxervate/cenegermin): https://www.drugpatentwatch.com/
What I need from you to give exact end dates
If you share:
1) your target market (US vs EU/UK, etc.), and
2) whether you want “patent expiry” or “market exclusivity” (or both),
I can summarize the specific protection timeline for Oxervate in that jurisdiction using the available patent listings.
Sources
- DrugPatentWatch - Oxervate / cenegermin